-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $23

Benzinga·09/03/2026 13:11:12
Listen to the news
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $30 to $23.